Eastern Canadian colorectal cancer consensus conference: Setting the limits of resectable disease

Current Oncology

Volumn 17, Issue 3, 2010, Pages 70-77

  Vickers, M ^a   Samson, B ⁿ   Colwell, B ^q   Cripps, C ^a   Jalink, D ^c   El Sayed, S ^a   Chen, E ^e   Porter, G ^q   Goel, R ^a   Villeneuve, J ^b   Sundaresan, S ^b   Asselah, J ^o   Biagi, J ^d   Jonker, D ^a   Dawson, L ^e   Letourneau, R ⁱ   Rother, M ^g   Maroun, J ^a   Thirlwell, M ^k   Hussein, M ^r   Tehfe, M ^j   Perrin, N ^p   Michaud, N ^p   Hammad, N ^c   Champion, P ^s   Rajan, R ^l   Burkes, R ^f   Barrette, S ^m   Welch, S ^h   Yarom, N ^a   Asmis, T ^a   more..

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

^d Cancer Centre of South Eastern Ontario   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g CREDIT VALLEY HOSPITAL   (Canada)

^h LONDON REGIONAL CANCER PROGRAM   (Canada)

ⁱ CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^j NOTRE DAME HOSPITAL   (Canada)

^k MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^l MONTREAL GENERAL HOSPITAL   (Canada)

^m Hôpital de Verdun   (France)

ⁿ HÔPITAL CHARLES LEMOYNE   (Canada)

^o CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^p Centre de Santé et de Services Sociaux de Sept Îles   (Canada)

^q QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^r Cape Breton Regional Hospital   (Canada)

^s PEI Cancer Treatment Centre   (Canada)

more..

Author keywords

Colorectal cancer; Consensus guideline; Gastric cancer; Gastrointes tinal neuroendocrine tumour

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CHROMOGRANIN A; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; KI 67 ANTIGEN; OCTREOTIDE; OXALIPLATIN; PANITUMUMAB; PLACEBO; STREPTOZOCIN; SUNITINIB; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE INTERVAL; ELDERLY CARE; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; LAPAROTOMY; LIVER BIOPSY; LIVER FUNCTION; LIVER METASTASIS; LIVER RESECTION; LUNG BIOPSY; LUNG CARCINOMA; LUNG LESION; LUNG METASTASIS; LUNG RESECTION; METASTASIS; MONOTHERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; RISK FACTOR; STOMACH CANCER; TUMOR VOLUME;

EID: 77953109261     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i3.610     Document Type: Article

References (65)

1. Canadian Task Force on Preventive Health Care. Canadian Task Force Methodology > Table 2. Levels of Evidence-Research Design Rating [Web archive]. Ottawa, ON: Canadian Task Force on Preventive Health Care; 2003. [Available online at: http//www.canadiantaskforce.ca/_archive/ctfphc&methods.htm#Table_2; cited: January 14, 2010
2. Nordlinger B, Van Cutsem E, Gruenberger T, et al. On behalf of the European Colorectal Metastases Treatment Group and the Sixth International Colorectal Liver Metastases Workshop. Combination of surgery and chemotherapy and the role of tar-geted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009;20:985-92.
3. Vergara V, Garripoli A, Marucci MM, Bonino F, Capussotti L. Olon cancer seeding after percutaneous fine needle aspiration f liver metastasis. J Hepatol 1993;18:276-8.
4. Terry R. Risks of needle biopsy of the liver. Br Med J 1952;1:1102-5.
5. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med 1993;118:96-8.
6. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by che-motherapy: a model to predict long-term survival. Ann Surg 2004;240:644-58.
7. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical mar-gin status on survival and site of recurrence after hepatic resec-tion for colorectal metastases. Ann Surg 2005;241:715-22.
8. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase iii study. J Clin Oncol 2008;26:2013-19.
9. Folprecht G, Gruenberger T, Hartmann JT, et al. Cetuximab plus folfox6 or cetuximab plus folfiri as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (celim-study) [abstract 296]. Proc Am Soc Clin Oncol Gastrointest Cancer Symp 2009;:. [Available online at: http//www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10212;cited April 6, 2010
10. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and che-motherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
11. Gruenberger B, Tamandl D, Schueller J, et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008;26:1830-5.
12. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006;243:1-7.
13. Lee MT, Kim JJ, Dinniwell R, et al. Phase i study of individual-ized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009;27:1585-91.
14. Rusthoven KE, Kavanagh BD, Cardenes H, et al. Multi-insti-tutional phase i/ii trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009;27:1572-8.
15. Mutsaerts EL, Zoetmulder FA, Meijer S, Baas P, Hart AA, Rutgers EJ. Outcome of thoracoscopic pulmonary metastasectomy evaluated by confirmatory thoracotomy. Ann Thorac Surg 2001;72:230-3.
16. Pfannschmidt J, Klode J, Muley T, Dienemann H, Hoffmann H. Nodal involvement at the time of pulmonary metasta-sectomy: experiences in 245 patients. Ann Thorac Surg 2006;81:448-54.
17. Veronesi G, Petrella F, Leo F, et al. Prognostic role of lymph node involvement in lung metastasectomy. J Thorac Cardiovasc Surg 2007;133:967-72.
18. Pastorino U, Veronesi G, Landoni C, et al. Fluorodeoxyglucose positron emission tomography improves preoperative stag-ing of resectable lung metastasis. J Thorac Cardiovasc Surg 2003;126:1906-10.
19. Long-term results of lung metastasectomy: prognostic analy-ses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997;113:37-49.
20. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras muta-tions and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
21. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
22. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009;27:2091-6.
23. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
24. Douillard J, Siena S, Cassidy J, Tabernero J, Burkes R. Random-ized phase 3 study of panitumumab with folfox4 compared to folfox4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mcrc): the prime trial [abstract 10LBA]. Eur J Cancer Suppl 2009;7:6.
25. Peeters M, Price T, Hotko Y, Cervantes A, Ducreux M. Random-ized phase 3 study of panitumumab with folfiri vs folfiri alone as second-line treatement (tx) in patients (pts) with metastatic colorectal cancer (mcrc) [abstract 14LBA]. Eur J Cancer Suppl 2009;7:9.
26. ImClone Systems. Data presented from two phase 3 Erbitux tudies in first-line metastatic colorectal cancer patients at joint 15th European Cancer Organisation and 34th European Soci-ety for Medical Oncology Multidisciplinary Congress [news release]. Branchburg, NJ: ImClone Systems; 2009. [Available online at: phx.corporate-ir.net/phoenix.zhtml?c=97689&p=irol-newsArticleID=1334885&highlight=; cited Novem-ber 24, 2009]
27. Cunningham D, Humblet Y, Siena S, et al. Cetuximab mono-therapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
28. Eddy DM. Screening for colorectal cancer. Ann Intern Med 1990;113:373-84.
29. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7.
30. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91.
31. Jackson McCleary NA, Meyerhardt J, Green E, et al. On behalf of the accent Collaborative Group. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage ii/iii colon cancer: findings from the accent database [abstract 4010]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: www.asco.org/ASCOv2/Meetings/ Abstracts?&vmview=abst_detail_view&confID=65&abstract ID=34878; cited April 6, 2010
32. Figer A, Perez-Staub N, Carola E, et al. Folfox in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the optimox1 study. Cancer 2007;110:2666-71.
33. Comella P, Natale D, Farris A, et al. Capecitabine plus ox-aliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the South-ern Italy Cooperative Oncology Group Trial 0108. Cancer 2005;104:282-9.
34. Chau I, Norman AR, Cunningham D, et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without exces-sive toxicity when treated with irinotecan monotherapy. Br J Cancer 2004;91:1453-8.
35. Folprecht G, Seymour MT, Saltz L, et al. Irinotecan/fluorou-racil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008;26:1443-51.
36. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (cairo): a phase iii randomised controlled trial. Lancet 2007;370:135-42.
37. Seymour MT, Maughan TS, Ledermann JA, et al. Different strat-egies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (mrc focus): a randomised controlled trial. Lancet 2007;370:143-52.
38. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Addi-tion of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009;27:199-205.
39. Powell ED, Asmis T, Jonker D, et al. Comorbidity and overall survival (os) in cetuximab-treated patients with advanced col-orectal cancer (acrc)-results from ncic ctg co.17: a phase iii trial of cetuximab versus best supportive care (bsc) [abstract 074]. J Clin Oncol 2009;27(suppl):. [Available online at: http/www.meeting.ascopubs.org/cgi/content/abstract/27/15S/4074; cited April 6, 2010]
40. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
41. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Berg-sland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23:3706-12.
42. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
43. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
44. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal in-cluding a grading system. Virchows Arch 2007;451:757-62.
45. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-con-trolled, double-blind, prospective, randomized study on the ef-fect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the promid Study Group. J Clin Oncol 2009;27:4656-63.
46. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold R. Combination therapy with octreotide and alpha-inter-feron: effect on tumor growth in metastatic endocrine gastroen-teropancreatic tumors. Am J Gastroenterol 1999;94:1381-7.
47. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG. Phase ii/ iii study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005;23:4897-904.
48. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cis-platin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
49. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-5.
50. Raoul JL, Niccoli P, Bang YJ, Borbath I, Lombard-Bohas C. Sunitinib (su) vs placebo for treatment of progressive, well-differentiated pancreatic islet cell tumours: results of a phase iii, randomised, double-blind trial [abstract O-6501]. Eur J Cancer Suppl 2009;7:361.
51. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxoru-bicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-71.
52. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006;24:2903-9.
53. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluo-rouracil, doxorubicin, and methotrexate in advanced esoph-agogastric cancer. J Clin Oncol 1997;15:261-7.
54. Ross P, Nicolson M, Cunningham D, et al. Prospective ran-domized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (pvi 5-fu) with epirubicin, cispla-tin, and pvi 5-fu in advanced esophagogastric cancer. J Clin Oncol 2002;20:1996-2004.
55. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase iii study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
56. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase iii noninfe-riority trial. Ann Oncol 2009;20:666-73.
57. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
58. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the toga trial: a phase iii study of trastuzumab added to stan-dard chemotherapy (ct) in first-line human epidermal growth factor receptor 2 (her2)-positive advanced gastric cancer (gc) [abstract LBA4509]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: http//www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33044;cited April 6, 2010
59. Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase ii study of the Gruppo Oncologico Italia Meridionale (goim). Anticancer Res 2003;23:4219-22.
60. Lee JL, Ryu MH, Chang HM, et al. A phase ii study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008;61:631-7.
61. Jo JC, Lee JL, Ryu MH, et al. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis. Jpn J Clin Oncol 2007;37:936-41.
62. Futatsuki K, Wakui A, Nakao I, et al. Late phase ii study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Gan To Kagaku Ryoho 1994;21:1033-8.
63. Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemo-therapy. Jpn J Clin Oncol 2004;34:8-13.
64. Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (bsc) as second-line therapy in gastric cancer: a randomized phase iii study of the Arbeits-gemeinschaft Internistische Onkologie (aio) [abstract 4540]. Proc Am Soc Clin Oncol 2009;27:. [Available online at: http//www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=31831;cited April 6, 2010]
65. Assersohn L, Brown G, Cunningham D, et al. Phase ii study of irinotecan and 5-fluorouracil/leucovorin in patients with pri-mary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 2004;15:64-9.